Pembrolizumab in mCRPC - Combination therapies as breakthrough to success?
Journal
Current opinion in urology
ISSN: 1473-6586
Titre abrégé: Curr Opin Urol
Pays: United States
ID NLM: 9200621
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
medline:
5
10
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICIs) have shown promising antitumor activity in various malignant diseases. This narrative review provides an update on ongoing clinical studies investigating the only FDA-approved ICI programmed death receptor 1 (PD-1) inhibitor pembrolizumab in mono- and combination therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Although most clinical trials investigating pembrolizumab as mono- or combinational therapy did not meet their primary endpoints, there exist subgroups of patients that demonstrate impressive responses rates justifying further investigation of ICI in prostate cancer. Beside combination of pembrolizumab with approved mCRPC agents, innovative approaches, like combining pembrolizumab with radioligands, deoxyribonucleic acid vaccines or innovative immunotherapeutic agents (i.e., ONC-392, AMG160, BXCL701) are ongoing exerting promising preliminary findings. ICI monotherapy seems to be effective in a small biomarker-preselected population, however, there is evidence that especially novel ICI combination approaches can improve patient survival, which could ultimately refocus and revolutionize the treatment of mCRPC.
Identifiants
pubmed: 37603022
doi: 10.1097/MOU.0000000000001121
pii: 00042307-990000000-00108
doi:
Substances chimiques
pembrolizumab
DPT0O3T46P
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents
0
Antibodies, Monoclonal
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
458-471Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Wang L, Lu B, He M, et al. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries From 2000 to 2019. Front Public Health 2022; 10:811044.
Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022; 386:1132–1142.
Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 2022; 399:1695–1707.
Saad F, Armstrong AJ, Thiery-Vuillemin A, et al. PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). JCO 2022; 40:11–111.
Clarke NW, Armstrong AJ, Thiery-Vuillemin Antoine, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid 2022; 1:oa2200043.
Motte N, Cornford P, van den Bergh RCN, et al. AU - EANM - ESTRO - ESUR - ISUP – SIOG Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress Milan 2023. https://uroweb.org/guidelines/prostate-cancer . [Accessed on 20/03/2023]
Vitkin N, Nersesian S, Siemens DR, et al. The Tumor immune contexture of prostate cancer. Front Immunol 2019; 10.
Heidegger I, Fotakis G, Offermann A, et al. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer. Mol Cancer 2022; 21:132.
U.S. Food and Drug Administration: FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication [accessed on 10/04/2023]
Wang I, Song L, Wang BY, et al. Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy. Am J Clin Exp Urol 2022; 10:210–233.
Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer genes. Nature 2013; 499:214–218.
Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 2018; 391:2128–2139.
Markowski MC, Shenderov E, Eisenberger MA, et al. Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. Prostate 2020; 80:407–411.
Taghizadeh H, Marhold M, Tomasich E, et al. Immune checkpoint inhibitors in mCRPC – rationales, challenges and perspectives. Oncoimmunology 2019; 8:e1644109.
Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol 2013; 34:556–563.
Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206:3015–3029.
Riley JL. PD-1 signaling in primary T cells. Immunol Rev 2009; 229:114–125.
Kinter AL, Godbout EJ, McNally JP, et al. The Common γ-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008; 181:6738–6746.
Hansen AR, Massard C, Ott PA, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol 2018; 29:1807–1813.
Antonarakis ES, Piulats Rodriguez JMM, Gross-Goupil M, et al. Biomarker analysis from the KEYNOTE-199 trial of pembrolizumab in patients (pts) with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). JCO 2020; 38:5526–15526.
Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol 2020; 38:395–405.
VA Office of Research and Development: A Phase 2 Study of a Checkpoint Inhibitor in Men With Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation. Identifier NCT04104893 https://clinicaltrials.gov/ct2/show/NCT04104893 ; 2020–2024 [accessed on 12/01/2023]
Institute of Cancer Research, United Kingdom: PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab for Patients Suffering From Metastatic Prostate Cancer. Identifier NCT03506997 https://clinicaltrials.gov/ct2/show/NCT03506997 ; 2018–2023 [accessed on 12/01/2023]
Graff JN, Beer TM, Alumkal JJ, et al. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. J Immunother Cancer 2020; 8:e000642.
Heidegger I, Necchi A, Pircher A, et al. A Systematic review of the emerging role of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: will combination strategies improve efficacy? Eur Urol Oncol 2021; 4:745–754.
Yu ∗Evan Y, Fong P, Piulats JM, et al. Pd16-12 pembrolizumab plus enzalutamide in abiraterone-pretreated patients with metastatic castration-resistant prostate cancer: updated results from keynote-365 cohort c. J Urol 2020; 203:e368–e1368.
Hoimes CJ, Graff JN, Tagawa ST, et al. KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC). JCO 2020; 38:5543–15543.
ESMO 2022: Linch M, Ferrario C, Stoeckle M. 1389P - Two-year follow-up of KEYNOTE- AQ8 365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). 2022; DOI: Annals of Oncology (2022) 33 (suppl_7): S616-S652. 10.1016/annonc/annonc1070 [Accessed 2 April 2023]
MD JG: A Phase II Single Arm Study of Fecal Microbiota Transplant (FMT) in Men With Metastatic Castration Resistant Prostate Cancer Whose Cancer Has Not Responded to Enzalutamide + Pembrolizumab. Identifier NCT04116775 https://clinicaltrials.gov/ct2/show/NCT04116775 ; 2019-2023 [accessed on 31/01/2023]
Yu EY, Kolinsky MP, Berry WR, et al. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study. Eur Urol 2022; 82:22–30.
2023; Petrylak DP, Ratta R, Matsubara N. Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): rrandomized, double-blind, phase 3 KEYNOTE-921 study. DOI: 10.1200/JCO.2023.41.6_suppl.19.
doi: 10.1200/JCO.2023.41.6_suppl.19
Jonsson Comprehensive Cancer Center: Phase Ib Trial of Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate. Identifier NCT03582475 https://clinicaltrials.gov/ct2/show/NCT03582475 ; 2018-2023 [accessed on 31/01/2023]
2023; Chin AI, Ly A, Rodriguez S. Updated results of a phase Ib single-center study of pembrolizumab in combination with chemotherapy in patients with locally advanced or metastatic small cell/neuroendocrine cancers of the prostate and urothelium. DOI: 10.1200/JCO.2022.40.6_suppl.510.
doi: 10.1200/JCO.2022.40.6_suppl.510
Fundacion Oncosur: A Phase 2 Clinical Trial of Pembrolizumab in Combination With Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resistant Prostate Cancer. Identifier NCT05563558 https://clinicaltrials.gov/ct2/show/NCT05563558 ; 2022–2026 [accessed on 02/02/2023]
University of California, San Francisco: Phase 2 Open Label Study of Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects. Identifier NCT03248570 https://clinicaltrials.gov/ct2/show/NCT03248570 ; 2018–2024 [accessed on 02/02/2023]
Merck Sharp & Dohme LLC: A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants With Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921). Identifier NCT04907227 https://clinicaltrials.gov/ct2/show/NCT04907227 ; 2020–2023 [accessed on 02/02/2023].
Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2020; 21:162–174.
Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015; 373:1697–1708.
Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 2017; 23:3711–3720.
Shen J, Zhao W, Ju Z, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res 2019; 79:311–319.
Yu EY, Piulats JM, Gravis G, et al. Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b/2 KEYNOTE-365 cohort A study. Eur Urol 2023; 83:15–26.
Merck Sharp & Dohme LLC: A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment With One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010). Identifier NCT03834519 https://clinicaltrials.gov/ct2/show/study/NCT03834519 ; 2019–2022. [accessed on 04/02/2023]
ESMO 2022: Pembrolizumab + Olaparib Versus Abiraterone or Enzalutamide for Patients with Previously Treated mCRPC: Randomized Open-Label Phase 3 KEYLYNK-010 Study. DOI: Annals of Oncology (2022) 33 (suppl_7): S616-S652.10.1016/annonc/annonc107010.1136/jitc-2021-004198; [accessed on 04/02/2023]
Mehra N, Antonarakis ES, Park SH, et al. Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC) 2023; DOI: 10.1200/JCO.2023.41.6_suppl.131.
doi: 10.1200/JCO.2023.41.6_suppl.131
MD AC: A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC). Identifier NCT03093428 https://clinicaltrials.gov/ct2/show/NCT03093428 ; 2022.
Hofman MS, Emmett L, Sandhu S, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 2021; 397:797–804.
Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021; 385:1091–1103.
Sandhu S, Joshua AM, Emmett L, et al. PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). JCO 2022; 40:5017–15017.
Aggarwal RR, Luch Sam S, Koshkin VS, et al. Immunogenic priming with 177Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study. JCO 2021; 39:5053–15053.
Sun MP, Nauseef JT, Palmer J, et al. Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591. 2023. DOI: 10.1200/JCO.2023.41.6_suppl.181 J Clin Oncol 41, no. 6_suppl
McNeel DG, Dunphy EJ, Davies JG, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009; 27:4047–4054.
McNeel DG, Eickhoff JC, Wargowski E, et al. Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC). J Immunother Cancer 2022; 10:e004198.
University of Wisconsin, Madison: Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer. Identifier NCT04090528 https://clinicaltrials.gov/ct2/show/NCT04090528 ; 2022.
Stein MN, Fong L, Tutrone R, et al. ADXS31142 immunotherapy ± pembrolizumab treatment for metastatic castration-resistant prostate cancer: open-label phase I/II KEYNOTE-046 Study. Oncologist 2022; 27:453–461.
Chou H-Y: OncoC4 - Oncoc4 Announces Fast Track Designation Granted By The U.S. FDA For ONC-392 Monotherapy In PD(L)1-Resistant NSCLC. [accessed on 05/02/2023]
OncoC4, Inc.: Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001). Identifier NCT04140526 https://clinicaltrials.gov/ct2/show/NCT04140526 ; 2020-2023; [accessed on 05/02/2023]
Tran B, Horvath L, Dorff T, et al. 609O - Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) 2020.
Patel M, Lum LG, Deol A, et al. Phase II trial of a novel immunotherapy combination of pembrolizumab and HER2 bi-armed activated T cells (BATs) in metastatic castrate resistant prostate cancer. JCO 2020; 38:97–197.
Jindal T, Han H, Deshmukh PS, et al. 1404P - A phase II study of ZEN-3694 (ZEN), enzalutamide (ENZ), and pembrolizumab (P) in metastatic castration resistant prostate cancer (mCRPC): Interim safety results 2022.
Merck Sharp & Dohme LLC: A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors. Identifier NCT03473925 https://clinicaltrials.gov/ct2/show/study/NCT03473925 ; 2018-2021 [accessed on 05/02/2023]
Aggarwal RR, Zhang J, Zhu X, et al. First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: Phase 2a final results 2023; DOI: 10.1200/JCO.2023.41.6_suppl.176.
doi: 10.1200/JCO.2023.41.6_suppl.176
Yoshida T, Yaegashi H, Toriumi R, et al. Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report. Front Oncol 2022; 12:912490.
Berger BT, Labriola MK, Antonarakis ES, et al. Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline CHEK2 mutation. BMJ Case Rep 2023; 16:e251320.
Merseburger AS, Waldron N, Ribal MJ, et al. Genomic testing in patients with metastatic castration-resistant prostate cancer: a pragmatic guide for clinicians. Eur Urol 2021; 79:519–529.
Merck & Co., Inc., Rahway, NJ, USA and its affiliates: Select Adverse Reactions for KEYTRUDA® (pembrolizumab) | HCP https://www.keytrudahcp.com/safety/adverse-reactions/ [accessed on 09/072023)